Țară: Canada
Limbă: engleză
Sursă: Health Canada
IPRATROPIUM BROMIDE
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
R03BB01
IPRATROPIUM BROMIDE
250MCG
SOLUTION
IPRATROPIUM BROMIDE 250MCG
INHALATION
20ML
Prescription
ANTIMUSCARINICS ANTISPASMODICS
Active ingredient group (AIG) number: 0115643001; AHFS:
CANCELLED POST MARKET
2007-10-11
_ _ _ _ _Page 1 of 33_ PRODUCT MONOGRAPH Pr Atrovent ® (Ipratropium Bromide) INHALATION SOLUTION (20 mL bottle, 1 mL and 2 mL Unit Dose Vials) BRONCHODILATOR Boehringer Ingelheim (Canada) Ltd. 5180 South Service Road, Burlington, Ontario L7L 5H4 Date of Preparation: September 19, 2003 Date of Revision: May 16, 2006 Submission Control No:104456 BICL BPI # 0013-05, #0014-06, #0022-05 _ _ _ _ _Page 2 of 33_ Table of Contents [To update, right-click anywhere in the Table of Contents and select “Update Field”, “Update entire table”, click OK.] PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS....................................................................................................5 DRUG INTERACTIONS ....................................................................................................9 DOSAGE AND ADMINISTRATION..............................................................................10 OVERDOSAGE ................................................................................................................10 ACTION AND CLINICAL PHARMACOLOGY ............................................................11 STORAGE AND STABILITY..........................................................................................13 SPECIAL HANDLING INSTRUCTIONS .......................................................................14 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................14 PART II: SCIENTIFIC INFORMATION ...................................................... Citiți documentul complet